A prospective follow-up of irAEs involving 1,187 cancer patients using anti–PD-1/L1 surprisingly identified factors associated with poor prognosis in solid cancer patients, such as elevated NLR and performance status (PS) ≥ 2 predicted very severe irAE and fatal irAE, and albumin levels < 35 g/liter predicted fatal irAE (80). The gene discussed is PDCD1; the disease is cancer.